Unique ID issued by UMIN | UMIN000013886 |
---|---|
Receipt number | R000015990 |
Scientific Title | A phase II study of neoadjuvant epirubicin/cyclophosphamide (EC) followed by weekly nanoparticle albumin-bound paclitaxel with trastuzumab for HER2-positive breast cancer |
Date of disclosure of the study information | 2014/05/06 |
Last modified on | 2016/05/11 10:02:17 |
A phase II study of neoadjuvant epirubicin/cyclophosphamide (EC) followed by weekly nanoparticle albumin-bound paclitaxel with trastuzumab for HER2-positive breast cancer
A phase II study of neoadjuvant epirubicin/cyclophosphamide (EC) followed by weekly nanoparticle albumin-bound paclitaxel with trastuzumab for HER2-positive breast cancer
A phase II study of neoadjuvant epirubicin/cyclophosphamide (EC) followed by weekly nanoparticle albumin-bound paclitaxel with trastuzumab for HER2-positive breast cancer
A phase II study of neoadjuvant epirubicin/cyclophosphamide (EC) followed by weekly nanoparticle albumin-bound paclitaxel with trastuzumab for HER2-positive breast cancer
Japan |
Breast cancer
Hematology and clinical oncology | Breast surgery |
Malignancy
NO
The aim of this phase II study is to evaluate the efficacy and toxicity of EC (epirubicin/cyclophosphamide) followed by weekly nab-PTX with trastuzumab as a neoadjuvant therapy for HER2-positive breast cancer.
Safety,Efficacy
Exploratory
Pragmatic
Phase II
pathological CR(pCR) rate
The breast conserving rate, toxicities, feasibility, overall survival, and relapse-free survival
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
Patients receive four cycles of epirubicin (90 mg/m2) and cyclophosphamide (600 mg/m2) every 3 weeks, followed by four cycles of nab-PTX (100 mg/m2) on days 1, 8 and 15 in a 28-day cycle. Fifteen cycles of trastuzumab (2 mg/kg, loading 4 mg/kg) are added to the nab-PTX regimen every week.
20 | years-old | <= |
70 | years-old | >= |
Female
1)Patients with histologically diagnosed invasive breast cancer.
2)Resectable case
3)Category of the T2-4, N0-3, M0.
4)Without previous operation or chemotherapy
5)With measurable lesions
6)ECOG performance status 0-2
7)Adequate organ function
8)Written informed concent
Severe complications
history of hypersensitivity reaction for important drug in this study
Bilateral breast cancer
Inflammatory breast cancer
Pregnant or nursing women
30
1st name | |
Middle name | |
Last name | Tadao Shimizu |
Tokyo Women's Medical University, Medical Center East
Department of Breast Surgery
2-1-10, Nishi-ogu, Arakawa-ku,
03-3810-1111
shimitsu@dnh.twmu.ac.jp
1st name | |
Middle name | |
Last name | Akira Hirano |
Tokyo Women's Medical University, Medical Center East
Department of Breast Surgery
2-1-10, Nishi-ogu, Arakawa-ku,
03-3810-1111
ahirasu@dnh.twmu.ac.jp
Tokyo Women's Medical University
None
Self funding
Japan
Tokyo Women's Medical University, Yachiyo Medical Center
None
NO
東京女子医科大学東医療センター(東京都)、東京女子医科大学八千代医療センター(千葉県)
2014 | Year | 05 | Month | 06 | Day |
Unpublished
Open public recruiting
2014 | Year | 05 | Month | 01 | Day |
2014 | Year | 05 | Month | 01 | Day |
2022 | Year | 04 | Month | 30 | Day |
2022 | Year | 04 | Month | 30 | Day |
2022 | Year | 05 | Month | 31 | Day |
2022 | Year | 05 | Month | 31 | Day |
2014 | Year | 05 | Month | 06 | Day |
2016 | Year | 05 | Month | 11 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015990
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |